Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo

This publication has 26 references indexed in Scilit:

• A Neoepitope‐Based Enzyme Immunoassay for Quantification of C1‐Inhibitor in Complex with C1r and C1s
  Scandinavian Journal of Immunology, 1997
• Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes in fully heparinized patients: a European multicentre study
  European Journal of Cardio-Thoracic Surgery, 1997
• Circulating endothelin in cardiac operations: influence of blood pressure and endotoxin
  The Annals of Thoracic Surgery, 1996
• A New Model for Evaluation of Biocompatibility: Combined Determination of Neoepitopes in Blood and on Artificial Surfaces Demonstrates Reduced Complement Activation by Immobilization of Heparin
  Artificial Organs, 1995
• Modification of the Complement Binding Properties of Polystyrene: Effects of End‐Point Heparin Attachment
  Scandinavian Journal of Immunology, 1993
• Complement activation during bypass in acquired C1 esterase inhibitor deficiency
  The Annals of Thoracic Surgery, 1991
• Formation of C5a during cardiopulmonary bypass: Inhibition by precoating with heparin
  The Annals of Thoracic Surgery, 1991
• Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man
  Nature, 1985
• Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b
  Molecular Immunology, 1983
• A postulated mechanism for heparin's potentiation of C1 inhibitor function
  Molecular Immunology, 1982